Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Advanced Solid Tumor 13Leukemia, Myeloid, Acute 10Carcinoma, Non-Small-Cell Lung 7Advanced Solid Tumors 7Breast Neoplasms 6Solid Tumor 5Pancreatic Neoplasms 5Melanoma 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Solid Tumors 3Recurrence 3Myelodysplastic Syndromes 3Lung Neoplasms 3Leukemia, Biphenotypic, Acute 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Biliary Tract Neoplasms 3Advanced Malignant Solid Tumor 3Advanced Lung Cancer 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

Thyrotropin Alfa 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Differentiated Thyroid Cancer × Injections × Clear all
NCT04137185 2024-03-06

Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Completed
64 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡